Acorda Therapeutics (ACOR) – Investment Analysts’ Recent Ratings Changes
Several brokerages have updated their recommendations and price targets on shares of Acorda Therapeutics (NASDAQ: ACOR) in the last few weeks:
- 8/2/2017 – Acorda Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
- 7/28/2017 – Acorda Therapeutics had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They wrote, “Alexion (ALXN) reported 2Q17 sales/earnings and provided a business update (PDF) to investors. The company had a strong 2Q17, reporting sales of $912M and non-GAAP EPS of $1.56, beating OPCO by 9% and 25% respectively. The strong beat was partially attributable to favorable one-offs in 1H17, with 2H17 expected to see weaker growth, which was well flagged by the company. The pipeline keeps moving along with a positive opinion for Soliris rMG in the EU in June and a PDUFA date of Oct. 23, 2017. We were particularly struck by new management’s ability to stabilize the business, provide transparency and the continuing strong fundamentals.””
- 7/19/2017 – Acorda Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
- 7/19/2017 – Acorda Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “Acorda’s key multiple sclerosis drug Ampyra is facing several patent challenges. Recently a district court invalidated four patents of, Ampyra, thereby making way for generic versions of the drug. Sales Ampyra also declined sequentially in the quarter. The company’s share price underperformed the industry so far this year. With Ampyra facing patent issues, focus has shifted to the company’s late stage parkinson’s candidates Inbrija (formerly known as CVT-301) and tozadenant. However, the company recently submitted regulatory applications for Inbrija in the U.S. and plans to file for the same in the EU by the end of 2017. Meanwhile, Acorda is working on expanding its pipeline by entering into deals and pursuing acquisitions. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters.”
- 7/13/2017 – Acorda Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
- 7/10/2017 – Acorda Therapeutics is now covered by analysts at Jefferies Group LLC. They set a “hold” rating and a $22.00 price target on the stock.
- 7/7/2017 – Acorda Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.16. The company had revenue of $139.40 million for the quarter, compared to analysts’ expectations of $139.81 million. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.07 EPS.
In other Acorda Therapeutics news, insider Andrew A. Hindman sold 7,704 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $15.75, for a total transaction of $121,338.00. Following the transaction, the insider now owns 46,123 shares of the company’s stock, valued at approximately $726,437.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ron Cohen purchased 20,000 shares of Acorda Therapeutics stock in a transaction on Friday, June 16th. The shares were acquired at an average cost of $16.95 per share, for a total transaction of $339,000.00. Following the purchase, the insider now owns 511,648 shares in the company, valued at $8,672,433.60. The disclosure for this purchase can be found here. Insiders have sold a total of 27,704 shares of company stock worth $553,638 in the last three months. Corporate insiders own 7.90% of the company’s stock.
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.